The genes involved in signal transduction are major candidates in association studies on affective disorders and responses to antidepressants. We investigated whether the C825T polymorphism of the b3 subunit of G protein (GNB3) gene is associated with the symptom severity or treatment response of major depressive disorders (MDDs) in a Korean sample of 106 MDD patients; our study also included 133 healthy controls. Hypertensive subjects were excluded from the study because association between GNB3 variants and hypertension has been reported in previous studies. We found significantly more carriers of the 825T allele in MDD patients than in normal controls (w 2 ¼ 6.37, P ¼ 0.012; OR ¼ 2.19, 95% CI 1.18-4.05). The T-allele carriers showed higher scores than those with the CC genotype in the baseline total and in some subcategories of the Hamilton Depression Rating Scale (Po0.05). We also found a statistically significant association between T-allele carriers and antidepressant treatment response (Po0.05). These results suggest that the T allele of the C825T polymorphism in the GNB3 gene is associated with MDD. It was also demonstrated that MDD patients bearing the T allele had a severe symptomatology and a better response to antidepressant treatment than patients without the T allele.
INTRODUCTION
Hundreds of cell-surface receptors for neurotransmitters and other ligands use G proteins to transduce intracellular signaling pathways. G proteins play important roles in determining the specificity and temporal characteristics of cellular responses to signals. Gb proteins form dimeric complexes with Gg subunits that interact with Ga subunits to generate a heterotrimeric G protein. Upon receptor activation, G proteins dissociate into free Ga and Gbg subunits that can activate various effectors. Effector proteins of the Gbg complex include phospholipases, adenylyl cyclases, ion channels, G-protein-coupled receptor kinases, and phosphoinositide-3 kinases.
T allele of this SNP is associated with the occurrence of a splice variant (Gb3s) that leads to the deletion of 41 amino acids. The Gb3s variant has been reported to be not only associated with increased signal transduction and ion transport, but also with pathophysiological conditions such as hypertension [3] [4] [5] [6] [7] and obesity. 8, 9 More recently, Zill et al 10 found an association between the C825T SNP of GNB3 and depression. They reported that the frequency of the T allele was significantly higher in depressive patients than in healthy controls and schizophrenic patients. They also found a significant association between the TT genotype and responses to antidepressant treatment. Most recently, Serretti et al 11 reported the same results on treatment response to selective serotonin reuptake inhibitors in a large sample of depressive Italian patients. Bondy et al 12 also reported a significant increase in the GNB3T allele in depressive disorder, and that the TT genotype in the presence of the D allele of the angiotensin-I-converting-enzyme gene is associated with a more than five-fold increase in the risk of major depression. However, no association between depression and the GNB3T allele was found in an Asian population. 13, 14 In the present study, the relationships between the C825T SNP of the GNB3 gene and the clinical symptoms of major depressive disorders (MDDs) in a Korean sample of 106 MDD patients are compared with 133 healthy controls. In addition, the association between the C825T SNP and antidepressant therapeutic response was tested.
RESULTS
The genotypes and allele distributions for the GNB3 C825T SNP for the MDD patients and controls are given in Table 1 Table 1) . Table 2 presents a comparison of characteristics between genotype groups of the MDD patients, including sex, age, baseline symptom clusters, and therapeutic response. Significant differences between the two subject groups were present in the baseline total, core, psychic anxiety, and delusion HAM-D scores, and in the baseline CGI-S scores (Table 2) . A total of 106 of the MDD patients completed 8 weeks of antidepressant treatment and underwent evaluation using the HAM-D and CGI-S scores. There were no significant differences in end-point (8-week) total and subcategory HAM-D scores (total HAM-D scores; TT ¼ 7.376.4, TC ¼ 6.574.9, CC ¼ 8.776.2; F ¼ 0.97, P ¼ 0.38; the other data were not presented). However, the percentage changes in the HAM-D (total and psychic anxiety) score and CGI-S score after 8-week treatment were higher for the T þ genotype group than for the TÀ group (Table 2) . Further, the responder percentage was higher for the T þ group than for the TÀ group. Interestingly, however, frequencies of remitters were not significantly different between the subject groups ( Table 2) .
DISCUSSION
The results of our study suggest that the T allele of a functional polymorphism (C825T) in the GNB3 gene is associated with MDD. It was also demonstrated that MDD patients bearing the T allele had a more severe symptomatology and a better response to antidepressant treatment than patients without it. Although this finding is consistent with previous studies in Caucasians, 4, 10, 12 it differs from that in a Japanese population. 13 The frequencies of the T allele in Asian populations (42-53%) are different from those in Caucasians (27-42%). In the Japanese sample of the study of Kunugi et al, 13 the frequency of the T allele was 0.53 in both depressive and Association between GNB3 gene and depression H-J Lee et al control groups. However, in our Korean sample, the frequencies of the T allele were significantly different between depressive and control groups, at 0.54 and 0.44, respectively. Unfortunately, GNB3T allele frequency has never been reported in Korean population previously, so we could not compare our data with other Korean data. Tallele frequency of 0.44 in our controls is similar to those in controls of a Taiwanese (43.5%) 15 and a Chinese (47.7%) 8 population, although it is somewhat different from another Taiwanese study (50.0%). 14 Thus, we cautiously suggest that it is unlikely that the allele frequencies obtained in this study were due to sampling problems or genotyping errors.
The T allele was associated with Gb3s, a splice variant of GNB3 in which nucleotides 498-620 of exon 9 were deleted. This deletion causes the loss of 41 amino acids, producing a shortened, more active, splice variant of GNB3. Evidence from transient-expression experiments suggests that Gb3s is a biologically active protein that enhances signal transduction. 3, 16, 17 Recently, Rosskopf et al 18 reported that Gb3s-containing G protein results in an increased number of activated Gas and free Gbg dimers, which subsequently activate the downstream effector systems.
From the results of the present study, we hypothesize that the Gb3s variant related with the 825T allele is associated with the vulnerability to depression and severe depressive symptoms, especially in core depressive symptom, psychic anxiety, and delusion. We also suggest that the Gb3s variant is related to better and faster treatment responses due to enhanced signal transduction. It should be pointed out that the GNB3 825T allele carrier status was not related to the remission rate after the 8-week antidepressant treatment. This result indicates that the 825T allele of GNB3 is associated with the severity of depressive disorder and its improvement by antidepressant treatment, but not with end-point outcome after 8 weeks of antidepressant treatment.
It is also interesting that significant effects of T-allele carriers on depression and therapeutic response in our study might support the dominant effect of the Gb3s variant, as has been reported previously. 3 On the other hand, some studies have suggested a recessive effect concerning the therapeutic response of antidepressants. 10, 11 There are several limitations in this study. Firstly, the age distribution differed between MDD patients and controls, in that the mean age of the controls was substantially lower than that of patients. It is possible that some individuals in the control group will develop depressive disorder in later life, which may have lessened the difference between two groups. Secondly, we did not control the use of medication, and hence we could not completely exclude the effects of Association between GNB3 gene and depression H-J Lee et al the different medication; however, there was no significant difference in the classes of medications used. Furthermore, because all antidepressants have direct or indirect effects on G proteins, our results are valuable, irrespective of the antidepressant administered. Thirdly, another limitation is that hypertensive patients were excluded in our samples. Although the association data on hypertension and GNB3 are divergent, the possibility remains that GNB3 825T alleles are enriched in hypertensive individuals. Since hypertension prevalence increases with age, excluding hypertensives in control and MDD, patient groups which differ by 4 years could confound the outcome of this study. Fourthly, the relatively small sample size limits the generalizability of our findings. Future studies should use a larger-sized sample, and should control the drugs as well as other confounding factors.
In conclusion, our results might suggest that the investigated GNB3 C825T polymorphism is a predisposing factor for MDD, and is associated with the depressive symptom severity. We also found that the 825T allele was statistically significantly associated with a better clinical response to antidepressant treatment. These results can be explained by more rapidly occurring adaptive changes in 825T allele carrier with increased signal transduction.
MATERIALS AND METHODS

Subjects
A total of 106 MDD patients were included in this study (age, 47.1713.3 (mean7SD) years; age at onset, 43.3714.6 years; male : female, 28 : 78). It was the first episode of MDD in 16% of the patients, while the other 84% had several episodes before (mean 3.4173.53). The proportion of outpatients vs inpatients was 79 and 21%, respectively. All subjects were examined by trained psychiatrists using the Structured Clinical Interview of the Korean version of the DSM-IV, 19 leading to diagnoses according to DSM-IV criteria. 20 The severity of depression was assessed using the 21-item Hamilton Depression Rating Scale (HAM-D) 21 and the Clinical Global Impressions of Severity (CGI-S) scale. 22 Only subjects with a minimum score of 18 on the HAM-D entered the study. Patients with severe medical illness were excluded in order to avoid cases with secondary depression. Patients with hypertension were also excluded, based on the findings that 825T allele of GNB3 is associated with hypertension, [3] [4] [5] [6] [7] although contradictive negative results have also been reported. [23] [24] [25] Subjects with a history of alcohol or drug dependence, neurological disorders, or any concomitant DSM-IV axis-I psychiatric disorders were also excluded. The control group of normals included 133 randomly selected individuals, who visited the hospital for regular health screening (a free biannual governmentfunded service provided to all adult Koreans).
After an initial examination of 185 case records, 30 subjects with a past history of major medical illness including hypertension or abnormal laboratory results were excluded. In all, 155 physically healthy subjects were interviewed by well-trained psychiatrists, of whom 22 subjects were excluded because they showed a past history or family history of substance abuse/dependence or major psychiatric disorders (eg, schizophrenia or mood disorders). Venous blood was drawn from each individual after obtaining written informed consent using a protocol approved by the Ethics Committee of the Korea University Medical Center. All of the sample population was Korean.
The 106 MDD patients received various classes of pharmacological treatment: 42.5% received selective serotonin reuptake inhibitors, 27.4% received serotonin and noradrenaline reuptake inhibitors, 18.9% received mirtazapine, 9.4% received nefazodone, and 1.9% received tricyclic antidepressants.
The therapeutic response was evaluated by calculating percentage reductions in total and subcategory HAM-D scores ((baseline scoreÀ8-week score) Â 100/(baseline score)). Responders were defined as those with a minimum 50% decrease in the HAM-D total score after 8 weeks of medication, while remitters were defined by a HAM-D total score of seven points or less after 8 weeks of medication. Ratings were assigned blind to genotyping.
Genotyping
Genomic DNA was extracted from leukocytes using a QIAamp Blood Kit (Qiagen, Germany). A polymerasechain-reaction-based method was used for genotyping of the C825T polymorphism in GNB3 gene, as described previously.
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Statistical analyses
The presence of Hardy-Weinberg equilibrium was tested with the w 2 -test for goodness of fit. To evaluate specific depressive-cluster symptoms, the HAM-D items were grouped according to the following factors, as described by Serretti et al:
26 core (items 1, 2, 7, 8, 10, 13), sleep (items 4-6), activity (items 7, 8), psychic anxiety (items 9, 10), somatic anxiety (items 11, 12, 13), and delusion (items 2, 15, 20) . Categorical data were analyzed using the w 2 -test. Differences for continuous variables were evaluated using Student's t-test or one-way analysis of variance, followed by the LSD multiple-range test for comparison among groups. The cutoff P-value was set at 0.05. A correction for multiple testing was not performed because of the explorative approach used for a genetically complex trait in which the relationship between genotype and phenotype has not been established, and thus such corrections might inappropriately increase the likelihood that real effects will be missed (ie, increased type-II error rates). 27 Statistical analyses were carried out using SPSS for Microsoft Windows.
